Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec-Research Center, Québec, QC G1V 4G2, Canada.
Bioimaging Platform, CHU de Québec-Research Center, Faculty of Medicine, Laval University, Québec, QC G1V 4G2, Canada.
Int J Mol Sci. 2021 Oct 17;22(20):11181. doi: 10.3390/ijms222011181.
Aminosteroid derivative RM-581 was previously identified as an endoplasmic-reticulum (ER) stress inducer with potent in vitro and in vivo anticancer activities. We report its evaluation in androgen-independent prostate cancer (PC-3) cells. RM-581 efficiently blocks PC-3 cell proliferation with stronger activity than that of a selection of known antineoplastic agents. This later also showed a synergistic effect with docetaxel, able to block the proliferation of docetaxel-resistant PC-3 cells and, contrary to docetaxel, did not induce cell resistance. RM-581 induced an increase in the expression level of ER stress-related markers of apoptosis, potentially triggered by the presence of RM-581 in the ER of PC-3 cells. These in vitro results were then successfully translated in vivo in a PC-3 xenograft tumor model in nude mice, showing superior blockade than that of docetaxel. RM-581 was also able to stop the progression of PC-3 cells when they had become resistant to docetaxel treatment. Concomitantly, we observed a decrease in gene markers of mevalonate and fatty acid pathways, and intratumoral levels of cholesterol by 19% and fatty acids by 22%. Overall, this work demonstrates the potential of an ER stress inducer as an anticancer agent for the treatment of prostate cancers that are refractory to commonly used chemotherapy treatments.
氨基甾体衍生物 RM-581 先前被鉴定为内质网 (ER) 应激诱导剂,具有强大的体外和体内抗癌活性。我们报告了其在雄激素非依赖性前列腺癌 (PC-3) 细胞中的评估。RM-581 能有效抑制 PC-3 细胞增殖,其活性强于多种已知的抗肿瘤药物。后者还与多西他赛具有协同作用,能够阻断多西他赛耐药的 PC-3 细胞的增殖,并且与多西他赛不同,它不会诱导细胞耐药性。RM-581 诱导与 ER 应激相关的凋亡标志物表达水平增加,这可能是由 RM-581 在 PC-3 细胞 ER 中的存在引发的。这些体外结果随后在裸鼠的 PC-3 异种移植肿瘤模型中成功转化为体内结果,显示出比多西他赛更优的阻断效果。RM-581 还能够阻止对多西他赛治疗产生耐药性的 PC-3 细胞的进展。同时,我们观察到甲羟戊酸和脂肪酸途径的基因标志物以及肿瘤内胆固醇水平降低了 19%,脂肪酸水平降低了 22%。总体而言,这项工作证明了 ER 应激诱导剂作为治疗对常用化疗治疗有抗性的前列腺癌的抗癌剂的潜力。